PharmTech Drug Digest 11.20
News|Articles|June 19, 2015

Biomax Informatics Collaborates with Pierre Fabre on Therapeutic Antibody Development

Biomax Informatics AG and Pierre Fabre announced that they have entered into a collaboration to create an integrated antibody sequence and knowledge database.

Biomax Informatics AG and Pierre Fabre announced that they have entered into a collaboration to create an integrated antibody sequence and knowledge database. Following a successful pilot project, Pierre Fabre has licensed Biomax's BioXM Knowledge Management Environment and agreed on a continuous refinement and expansion of the system for comprehensive support of their antibody development process.

Biomax used the BioXM Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre's antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have adopted the platform to collect and generate further knowledge.




Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.